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The drug discovery and development process has undergone dramatic 
changes particularly in the last decade. Progress in drug discovery has been 
fuelled by improvements in methodologies and technologies including 
automated high performance liquid chromatography (HPLC), fast HPLC, 
automated method development, LC-MS and high-throughput purification 
methods. During the drug discovery and development process, rugged 
analytical methods are highly desirable to evaluate early drug targets, drug 
metabolism, pharmacokinetics, process research, preformulation and 
formulations. In view of the continuous demand for stability indicating 
methods for maintaining the quality and safety of drugs and bioanalytical 
methods in clinical and pre-clinical studies during drug discovery, the present 
work has been proposed.  
The present thesis entitled “DEVELOPMENT OF LIQUID 
CHROMATOGRAPHY-MASS SPECTROMETRIC METHODS FOR 
ANALYTICAL AND BIOANALYTICAL APPLICATIONS” has been divided into 
six chapters.  
Chapter 1 deals with a brief introduction on role of liquid chromatography and 
mass spectrometry in drug discovery & development. 
Chapter 2 deals with LC-ESI-MS/MS studies on forced degradation of abacavir 
sulphate an anti HIV drug. 
Chapter 3 deals with LC-ESI-MS/MS studies on forced degradation of 
indinavir suphate an anti HIV drug. 
Chapter 4 deals with development of an on-line two dimensional liquid 
chromatography combined with tandem mass spectrometric method for the 
determination of an antibiotic drug rifaximin in rat serum. 
Chapter 5 describes development and validation of a LC-ESI-MS method for 
determination of an antibiotic drug rifaximin on dried blood spots using 
monolithic column.  
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Chapter 6 describes the development of an ionic liquid based dispersive liquid-
liquid micro extraction procedure for the extraction and determination of 
rifaximin in rat serum by HPLC.  
Chapter 1: Role of liquid chromatography and mass spectrometry in drug 
discovery & development. 
This chapter gives a brief introduction to various roles of liquid 
chromatography in pharmaceutical analysis and bioanalysis. In modern 
pharmaceutical industry, high-performance liquid chromatography (HPLC) is 
the major and integral analytical tool applied at all stages of drug discovery, 
development, and production. At each phase analyses of various samples are 
performed to adequately control and monitor the quality of the prospective 
drug candidates, excipients, and final products, which require bioanalytical as 
well as stability indicating methods. 
Effective, eco-friendly and rapid method development is of paramount 
importance throughout the drug development life cycle. This requires a 
thorough understanding of HPLC principles and theory which lay a solid 
foundation for appreciating the many variables that are optimized during fast 
and effective HPLC method development and optimization. HPLC basics, types 
of chromatography, detectors, method development and validation are 
discussed briefly in this chapter. Hyphenated techniques such as LC-MS and 
LC-MS/MS were also discussed.  
In lieu of continuous demand for stability indicating and bioanalytical 
methods the work has been divided into two parts. Part A deals with 
development of stability indicating methods and part B with development of 
bioanalytical methods. The model drugs rifaximin, abacavir sulphate and 
indinavir sulphate were chosen and following objectives had been set:  
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Part A: Development of stability indicating methods 
i. LC-MS/MS studies on forced degradation of abacavir sulphate. 
ii. LC-MS/MS studies on forced degradation of indinavir sulphate. 
Part B: Development of Bioanalytical methods 
iii. On-line 2D-LC-ESI-MS/MS determination of rifaximin in rat serum 
iv. LC-ESI-MS determination of rifaximin on dried blood spots 
v. Ionic liquid based dispersive liquid-liquid microextraction and 
determination of rifaximin in rat serum 
Part A: Development of stability indicating methods 
Chapter 2: LC–MS/MS studies on forced degradation of abacavir sulphate. 
Abacavir sulphate (ABC) was subjected to forced degradation under the 
conditions of hydrolysis (acid, alkali and neutral), oxidation, photolysis and 
thermal stress. It resulted to eight degradation products. In case of acid 
hydrolysis drug was degraded completely. Hence its kinetic behaviour at 
temperatures 50 and 65 oC was also studied. Rate constant, half-life and t90 of 
the drug were also calculated. The rate constant was increased from 0.0474 to 
0.0064 h-1 as temperature increase from 50 to 65 oC. Abacavir sulphate and its 
degradation products separation was accomplished on Waters XTerra C18 (250 
mm ×4.6 mm, 5µm) column using 20 mM ammonium acetate: acetonitrile as a 
mobile phase in gradient elution mode. Based on the LC-MS/MS data the 
structure of degradation products and their fragmentation pathways were 
proposed. The proposed structures (Fig. 1) and fragmentation pathway was 
confirmed by HRMS data which provide accurate mass measurements. 
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Fig. 1 The chemical structures of proposed degradation products of ABC. 
Chapter 3: LC–MS/MS studies on forced degradation of indinavir sulphate. 
Indinavir sulphate (IDV) was subjected to acid hydrolysis, base 
hydrolysis, neutral hydrolysis, oxidation in presence of hydrogen peroxide and 
AIBN, thermal degradation and photo degradation. Total six degradation 
products were formed. Among the six degradation products three were from 
acid hydrolysis, two from oxidation and one of the degradation products 
obtained from neutral hydrolysis also. Indinavir sulphate and its degradation 
products were well separated on Waters XTerra C18 column. Based on the LC-
MS/MS data the structure of degradation products and their fragmentation 
pathways were proposed. The proposed structures (Fig. 2) and fragmentation 
pathways were confirmed by HRMS data. The oxidation degradation products 
obtained in this study are the important metabolites of indinavir sulphate 
formed in human body. 
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Fig. 2 The chemical structures of proposed degradation products of IDV. 
Part B: Development of Bioanalytical methods  
Chapter 4: On-line 2D-LC-ESI-MS/MS determination of rifaximin in rat 
serum. 
This chapter describes the  development of a direct injection method for 
the determination of rifaximin in rat serum. To facilitate this method two 
dimensional liquid chromatography was employed. The 2D-LC-ESI/MS/MS 
system consisted of a restricted access media column for trapping proteins as 
the first dimension and a Waters C18 column as second dimension using 0.1% 
aqueous acetic acid: acetonitrile as mobile phase in a gradient elution mode. 
2D-LC could be performed in either on-line or off-line modes. The on-line 
approach narrows the choice of LC mode because of the mobile phase 
compatibility for direct transfer to the second dimension. This approach 
minimizes sample losses, which is an advantage for sensitivity compared with 
the off-line mode. 
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Chapter 5: LC-ESI-MS determination of rifaximin on dried blood spots. 
This chapter describes the suitability of dried blood spot (DBS) technique 
was evaluated for sample collection. A patient can collect blood samples from 
finger prick on a blood spot card without much special training to a clinic for 
analysis. A high-throughput liquid chromatography–electrospray ionization 
mass spectrometric (LC–ESI-MS) method for screening of rifaximin on DBS was 
developed and validated. It involves solvent extraction of a punch of DBS (Fig. 
3) followed by reversed-phase LC on a relatively new monolithic column 
consisting of a silica rod with bimodal pore structure and detection by ESI-MS. 
 
Fig. 3 Optimized method for processing and extraction of rifaximin from DBS.  
 
Chapter 6: Ionic liquid based dispersive liquid-liquid microextraction and 
determination of rifaximin in rat serum. 
An efficient and environmental friendly ionic liquid based dispersive 
liquid-liquid micro extraction followed by RP-HPLC method for determination of 
rifaximin in rat serum was developed (Fig. 4). A water immiscible 1-butyl-3-
methylimidazolium hexafluorophosphate (BmimPF6), was found to be an 
effective extraction solvent among the five ionic liquids tried in the present 
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investigation. The effects of ionic liquid, dispersive solvent, 
extractant/disperser ratio and salt concentration on sample recovery and 
enrichment were studied. Using BmimPF6 and methanol as extraction and 
dispersive solvents, the recovery was found to be more than 98% at an 
extractant/disperser ratio of 0.43. The recovery was further enhanced to 99.5% 
by the addition of 5.0% NaCl solution. Rifaximin extracted in to BmimPF6 was 
spiked with rifampicin used as an internal standard and directly injected on to 
a Waters XTerra® C18 (5 μm, 250 x 4.6 mm) column, using 0.1% aqueous acetic 
acid: acetonitrile (45:55, v/v) as a mobile phase in an isocratic mode of elution 
and detected at 239 nm using photo diode array detector by reverse phase high 
performance liquid chromatography. A 3-fold enhancement in detection limit 
was achieved compared to the previously reported extraction method using 
protein precipitation.  
 
 
 
 
 
 
 
 
 
Fig. 4 Schematic representation of optimized IL based DLLME of rifaximin from 
rat serum. 
